IFNG and Blau syndrome: Thus, the use of anti-TNF antibodies for Blau syndrome treatment is appropriate in the sense that long-term administration of anti-TNF antibodies may correct the abnormalities that occur in the early progenitor stage by blocking the autoinflammatory loop and restoring the threshold for which IFNγ stimulation triggers an inflammatory response in macrophages (Figure 1).